177Lu-PSMA for advanced prostate cancer: are we ready to play big?
نویسندگان
چکیده
منابع مشابه
German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients.
177Lu-labeled PSMA-617 is a promising new therapeutic agent for radioligand therapy (RLT) of patients with metastatic castration-resistant prostate cancer (mCRPC). Initiated by the German Society of Nuclear Medicine, a retrospective multicenter data analysis was started in 2015 to evaluate efficacy and safety of 177Lu-PSMA-617 in a large cohort of patients. METHODS One hundred forty-five pati...
متن کاملScreening for Prostate Cancer: Are We Ready?1
Prostate cancer, a common malignancy worldwide, and a dominating one in western countries, remains one of the great challenges in cancer control (1 , 2). Prognosis is poor in cases with spread beyond the gland (3), and therapeutic progress has been slow (4). At first glance, screening appears attractive. Indeed, lively interest and enthusiasm for screening have arisen in recent years, notably i...
متن کاملPSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617.
UNLABELLED Prostate-specific membrane antigen (PSMA) is an excellent target for radionuclide therapy of metastasized castration-resistant prostate cancer (mCRPC). Besides high affinity and long tumor retention, the DOTA-conjugated ligand PSMA-617 has low kidney uptake, making it an excellent choice for therapeutic application. We retrospectively report our experience with (177)Lu-PSMA-617-targe...
متن کاملAre we ready for the next big thing?
The Medical Journal of Australia ISSN: 0025729X 15 June 2009 190 12 687-688 ©The Medical Journal of Australia 2009 www.mja.com.au Health care reform system has been adept in responding to technologic our track record in responding to sociological chan and this gives cause for concern for the future. Health care use varies with age, with health care trated in t e last few years of life — typical...
متن کاملChemoprevention for breast cancer: are we ready?
Despite recent advances in the management of breast cancer, there has been no noticeable improvement in the mortality rate. In fact, the reported incidence of breast cancer is rising (7,2). Although early detection through mammography screening may contribute to this increase, the main causes have yet to be delineated (3). Factors that concern many investigators include changes in dietary habit...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: European Journal of Nuclear Medicine and Molecular Imaging
سال: 2020
ISSN: 1619-7070,1619-7089
DOI: 10.1007/s00259-020-05102-4